Literature DB >> 26122367

ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.

Shogo Tajima1, Yuichi Takashi2,3, Nobuaki Ito2, Seiji Fukumoto3, Masashi Fukuyama4.   

Abstract

Phosphaturic mesenchymal tumors (PMT) are the most common cause of tumor-induced osteomalacia (TIO) related to mesenchymal neoplasms. The lineage of differentiation of PMTs has not been elucidated in existing literature. Fourteen cases of PMT were analyzed for this study to elucidate its lineage. We used vascular and/or lymphatic endothelial markers for the immunohistochemical analysis, which included CD31, CD34, factor VIII-related antigen, podoplanin, Freund's leukemia integration site 1 (FLI1), and avian v-ets erythroblastosis virus E26 oncogene homolog (ERG). FLI1 and ERG were stained in all cases with proportion of immunopositive tumor cells largely more than 50 %; staining intensity was moderate or strong for both FLI1 and ERG. The tumor cells were stained with CD31 and/or CD34, with significantly less staining than observed for FLI1 and ERG. The tumor cells were completely immunonegative for factor VIII-related antigen and podoplanin. FLI1 and ERG are known to have considerable specificity to endothelial cells; ERG is more widely equipped in surgical pathology laboratories than FLI1. We concluded that ERG (or FLI1 if available) is useful marker for the diagnosis of PMT, and that PMTs may have an endothelial cell lineage.

Entities:  

Keywords:  CD31; CD34; ERG; FLI1; Phosphaturic mesenchymal tumor

Mesh:

Substances:

Year:  2015        PMID: 26122367     DOI: 10.1007/s00795-015-0115-2

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  20 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Bone       Date:  2007-01-04       Impact factor: 4.398

3.  ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.

Authors:  Thomas M Schneider; Adeboye O Osunkoya
Journal:  Mod Pathol       Date:  2014-01-10       Impact factor: 7.842

Review 4.  Neuroendocrine cell markers for pancreatic islets and tumors.

Authors:  Guida Maria Portela-Gomes; Gerhard W Hacker; Raimund Weitgasser
Journal:  Appl Immunohistochem Mol Morphol       Date:  2004-09

5.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia.

Authors:  H Nakahama; T Nakanishi; H Uno; T Takaoka; N Taji; O Uyama; O Kitada; M Sugita; A Miyauchi; T Sugishita
Journal:  Urol Int       Date:  1995       Impact factor: 2.089

Review 6.  Fibroblast growth factor 23: state of the field and future directions.

Authors:  Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins
Journal:  Trends Endocrinol Metab       Date:  2012-08-24       Impact factor: 12.015

7.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Authors:  Michelle Houang; Adele Clarkson; Loretta Sioson; Marianne S Elston; Roderick J Clifton-Bligh; Michael Dray; Dominique Ranchere-Vince; Anne-Valerie Decouvelaere; Arnaud de la Fouchardiere; Anthony J Gill
Journal:  Hum Pathol       Date:  2013-09-20       Impact factor: 3.466

8.  Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung.

Authors:  M van de Rijn; C M Lombard; R V Rouse
Journal:  Am J Surg Pathol       Date:  1994-08       Impact factor: 6.394

9.  Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor.

Authors:  M Miettinen; A E Lindenmayer; A Chaubal
Journal:  Mod Pathol       Date:  1994-01       Impact factor: 7.842

10.  Solitary fibrous tumor. Consistent CD34 immunoreactivity and occurrence in the orbit.

Authors:  W H Westra; W L Gerald; J Rosai
Journal:  Am J Surg Pathol       Date:  1994-10       Impact factor: 6.394

View more
  4 in total

Review 1.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

2.  Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms.

Authors:  Yu-Chien Kao; Uta Flucke; Astrid Eijkelenboom; Lei Zhang; Yun-Shao Sung; Albert J H Suurmeijer; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-04       Impact factor: 6.394

4.  Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.

Authors:  Lulu Sun; Carina Dehner; Jason Kenney; Samantha M McNulty; Xiaopei Zhu; John D Pfeifer; Horacio M Maluf; John S A Chrisinger
Journal:  Virchows Arch       Date:  2020-11-05       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.